PBR Nachrichten

 

The companies will integrate the Genialis Supermodel with Inventia's RASTRUM 3D cell model platform to study pancreatic ductal adenocarcinoma (PDAC) and test therapeutic hypotheses. Initial findings from the The post Genialis and Inventia to enhance pancreatic cancer treatment testing appeared first on Pharmaceutical Business review....

S32 led the oversubscribed financing round. Investors included Catalio Capital Management, European Tech Collective, and Firebrand River Capital. Other backers were Nvidia, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, The post Basecamp Research secures $140m for AI-driven therapies appeared first on Pharmaceutical Business review....

The agreement includes an upfront payment, as well as potential development, regulatory, and sales milestone payments for BoomRay, along with possible royalties on future global net sales. The The post BoomRay and Novartis Pharma sign $900m deal for radioligand therapy appeared first on Pharmaceutical Business review....

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation, The post Boehringer and Envisagenics to develop precision cancer therapies appeared first on Pharmaceutical Business review....

The company said programmes could be onboarded at the facility immediately, rather than after a construction and qualification period, with the site intended to support clinical and commercial The post Made Scientific acquires cell therapy facility in Pennsylvania, US appeared first on Pharmaceutical Business review....

The authorisation allows both treatments to be used for patients with primary hypercholesterolaemia, including those with heterozygous familial and non-familial forms or mixed dyslipidaemia. This is said to The post EC approves Menarini and NewAmsterdam's obicetrapib therapies appeared first on Pharmaceutical Business review....

The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales milestones. The The post Telix to acquire ITM in deal worth up to $2.35bn appeared first on Pharmaceutical Business review....

The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has estimated global The post Sandoz and mAbxience agree on emicizumab biosimilar partnership appeared first on Pharmaceutical Business review....

The deal grants Ona Therapeutics rights to develop the ADC targeting a single undisclosed target. It includes an upfront payment from Ona Therapeutics to WuXi XDC, along with The post Ona Therapeutics to develop ADC with WuXi's payload-linker platform appeared first on Pharmaceutical Business review....

Under this arrangement, Dualitas will use its DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 new bispecific combinations. The company is set to receive $36.5m in The post Roche agrees $1bn deal with Dualitas for bispecific antibody research appeared first on Pharmaceutical Business review....

The collaboration, which marks Cellares' first development project in Asia, will explore adapting GenomeFrontier's virus-free process to the Cell Shuttle system. It aims to assist GenomeFrontier's clinical activities The post Cellares and GenomeFrontier to assess automated GF-CART01 production appeared first on Pharmaceutical Business review....

The approval covers patients with OSAS who continue to experience EDS while receiving treatment for airway obstruction. It also applies to narcolepsy with and without cataplexy, a condition The post Viatris' Wakix receives Japanese approval to treat OSAS and narcolepsy appeared first on Pharmaceutical Business review....

The arrangement offers a new regional pathway for long-acting HIV prevention in all PAHO Member States through its Regional Revolving Funds. The collaboration enables 14 countries, including Argentina, The post Gilead and PAHO agree to expedite lenacapavir access for HIV prevention appeared first on Pharmaceutical Business review....

The companies intend to work together on several research programmes focused on QurCan's Target-Engineered Responsive Polymer (TERP) polymer-lipid nanoparticle (PLNP) delivery platform development. QurCan uses its TERP platform The post Eli Lilly and QurCan sign genetic medicine deal appeared first on Pharmaceutical Business review....

Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm. The partnership expands on a working relationship between the two companies, which began in 2014. The post Cheplapharm to take over 20 medicines and three sites from Sanofi appeared first on Pharmaceutical Business review....

The revised guidance is intended for adults whose ES-SCLC has progressed after treatment with platinum-based chemotherapy. It recommends a monitoring period ranging between six and eight hours in The post FDA reduces monitoring time for Amgen's Imdelltra infusions appeared first on Pharmaceutical Business review....

The agreement involves the use of Modalis' CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio's engineered muscle-tropic adeno-associated virus (AAV) capsid, EMC181. EMC181 is designed for The post Exegenesis Bio and Modalis sign research deal for Duchenne therapy appeared first on Pharmaceutical Business review....

A ribbon-cutting ceremony to mark the opening is scheduled for 24 September, with company leadership, employees, partners and community leaders expected to attend. According to ABEC, the site The post ABEC to expand global manufacturing network with new Wilson facility appeared first on Pharmaceutical Business review....

The financing was raised in a Series A round led by RA Capital Management, with participation from Forbion, Canaan Partners and other investors. Porustobart is a second-generation, Fc-enhanced The post Solstice Oncology secures $225m to drive porustobart's development for cancer appeared first on Pharmaceutical Business review....

Insight Partners and Medical Excellence Capital led the round, with additional investment from Pfizer Ventures and M Ventures, the corporate venture capital arm of Merck KGaA, all joining The post TwoStep Therapeutics secures $62.5m funding to advance TS-104 appeared first on Pharmaceutical Business review....